sirukumab inn usan developmental code name tentative brand name plivensia human monoclonal antibody designed treatment rheumatoid acts proinflammatory cytokine interleukin sirukumab currently development johnson johnsons subsidiary started clinical reported phase ii december three phase iii trials sirroundd h collecting feb sirroundd considered met coprimary drug previously development treatment immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikisirukumab